TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16314640

Group type: EXPERIMENTAL
Intervention: Optimal debulking (≤ 2 cm residual disease)
Number of subjects: 1077

Group type: COMPARATOR
Intervention: UK patients with no visible residual disease
Number of subjects: 1077

Group type: COMPARATOR
Intervention: More extensive surgery in non-UK patients
Number of subjects: 1077
Study: 12160567

Group type: EXPERIMENTAL
Intervention: Alternating adaptation to red and green luminance‐varying gratings of different spatial frequencies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-color adaptation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Color-selective aftereffect
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Color-insensitive portion of the effect
Number of subjects: 0
Study: 9783503

Group type: EXPERIMENTAL
Intervention: Modified CPR (ventilation:compression ratio of 2:15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard CPR (ventilation:compression ratio of 1:5)
Number of subjects: 30
Study: 7945618

Group type: EXPERIMENTAL
Intervention: Hb A1C greater than 6.3%
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Ultrasound markers for fetal macrosomia
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Fetal diabetic complications
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Birthweight macrosomia
Number of subjects: 66
Study: 3285278

Group type: EXPERIMENTAL
Intervention: Levamisole (2.5 mg/kg/day on days 1 and 2 of each week for 18 months)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 31207648

Group type: EXPERIMENTAL
Intervention: SOP implemented weaning process
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Daily echocardiography
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Circulatory support with dobutamine
Number of subjects: 107

Group type: COMPARATOR
Intervention: Individual decisions weaning process
Number of subjects: 107
Study: 28669360

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE) therapy via telehealth
Number of subjects: 150

Group type: COMPARATOR
Intervention: Prolonged Exposure (PE) therapy in person
Number of subjects: 150
Study: 27265837

Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 2561
Study: 24508207

Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 mg twice daily
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study: 22481619

Group type: EXPERIMENTAL
Intervention: Fluconazole 150 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intra-vaginal fenticonazole 600 mg
Number of subjects: 80
Study: 20160158

Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg once daily for 4 days
Number of subjects: 24
Study: 17917786

Group type: EXPERIMENTAL
Intervention: Radical surgery
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conservative surgery
Number of subjects: 32
Study: 15950833

Group type: EXPERIMENTAL
Intervention: 15-week behavioral management program
Number of subjects: 116

Group type: COMPARATOR
Intervention: Usual care for heart failure
Number of subjects: 116
Study: 12653794

Group type: EXPERIMENTAL
Intervention: Ciclesonide (800 micro g twice daily)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 10578211

Group type: EXPERIMENTAL
Intervention: High-protein diet (HP; 45% protein, 25% carbohydrates, and 30% fat)
Number of subjects: 13

Group type: COMPARATOR
Intervention: High-carbohydrate diet (HC; 12% protein, 58% carbohydrates, and 30% fat)
Number of subjects: 13
Study: 8984701

Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 34
Study: 1816122

Group type: EXPERIMENTAL
Intervention: Single 1 g dose of cefotaxime
Number of subjects: 34

Group type: COMPARATOR
Intervention: Three doses of cefotaxime
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 500 mg metronidazole i.v. every 12 h for 72 h
Number of subjects: 34
Study: 6859365

Group type: EXPERIMENTAL
Intervention: Active surveillance system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive surveillance system
Number of subjects: 0
Study: 29236165

Group type: EXPERIMENTAL
Intervention: Dose 1 Curry (D1C)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dose 2 Curry (D2C)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dose 0 Control (D0C)
Number of subjects: 20
Study: 29914545

Group type: EXPERIMENTAL
Intervention: Endoscopic totally extraperitoneal (TEP) inguinal repair
Number of subjects: 160

Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 160
Study: 26901004

Group type: EXPERIMENTAL
Intervention: Inspiration
Number of subjects: 28

Group type: COMPARATOR
Intervention: Resting expiratory position
Number of subjects: 28
Study: 25049315

Group type: EXPERIMENTAL
Intervention: WL‐STE <1 mm
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: WL‐STE 1‐2 mm
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: WL‐STE >2 mm
Number of subjects: 763
Study: 20445204

Group type: EXPERIMENTAL
Intervention: Multiple-component intervention programs (PHAB + RAVE‐O; PHAB + WIST)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Control programs (CSS, MATH, phonological control)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Multiple-component programs
Number of subjects: 279
Study: 20719725

Group type: EXPERIMENTAL
Intervention: Kalangos ring annuloplasty (group 1, 67 patients)
Number of subjects: 129

Group type: COMPARATOR
Intervention: De Vega semicircular annuloplasty (group 2, 62 patients)
Number of subjects: 129
Study: 17385190

Group type: EXPERIMENTAL
Intervention: Supportive-expressive group therapy (SEGT) plus three classes of relaxation therapy
Number of subjects: 227

Group type: COMPARATOR
Intervention: Control group receiving three classes of relaxation therapy
Number of subjects: 227
Study: 16350553

Group type: EXPERIMENTAL
Intervention: 140 ml@4ml/s
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 140 ml = 60 ml@5ml/s + 80 ml@3ml/s
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 100 ml@4ml/s
Number of subjects: 45
Study: 11408506

Group type: EXPERIMENTAL
Intervention: VAC (vincristine, dactinomycin, cyclophosphamide), n = 235
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: VAI (vincristine, dactinomycin, ifosfamide), n = 222
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: VIE (vincristine, ifosfamide, etoposide), n = 236
Number of subjects: 883

Group type: COMPARATOR
Intervention: HF-RT (hyperfractionated radiotherapy)
Number of subjects: 883

Group type: COMPARATOR
Intervention: C-RT (conventional radiotherapy)
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: VA chemotherapy
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: Nonrandomized patient subsets
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: Age > 10 years with paratesticular primaries
Number of subjects: 883
Study: 9723149

Group type: EXPERIMENTAL
Intervention: Combination of referral strategies (fixed appointment, involvement of the family, presence of the aftercare person, motivational counselling)
Number of subjects: 0
Study: 7994812

Group type: EXPERIMENTAL
Intervention: Trapidil 100 mg TID
Number of subjects: 254

Group type: COMPARATOR
Intervention: Aspirin 100 mg TID
Number of subjects: 254
Study: 2657296

Group type: EXPERIMENTAL
Intervention: Normal saline with epinephrine (1:200,000)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% with epinephrine (1:200,000)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Normal saline
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no infiltration)
Number of subjects: 42
Study: 31693545

Group type: EXPERIMENTAL
Intervention: Offset analgesia (OA) response in patients with migraine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 26
Study: 31022555

Group type: EXPERIMENTAL
Intervention: Literacy-adapted group cognitive-behavioral therapy (CBT)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Pain psychoeducation groups (EDU)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 241
Study: 27830950

Group type: EXPERIMENTAL
Intervention: Recall of partner successfully resisting a cigarette
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Recall of partner failing to resist a cigarette
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control condition (no recall)
Number of subjects: 131
Study: 26498386

Group type: EXPERIMENTAL
Intervention: Roflumilast 125, 250, and 500 μg
Number of subjects: 4873

Group type: EXPERIMENTAL
Intervention: Roflumilast 500 μg with 400 μg BDP
Number of subjects: 4873

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4873
Study: 23356382

Group type: EXPERIMENTAL
Intervention: Telemonitoring intervention
Number of subjects: 133
Study: 20383545

Group type: EXPERIMENTAL
Intervention: 10% casein phosphopeptide‐amorphous calcium phosphate (CPP‐ACP) applied once daily (Tooth Mousse, GC Europe)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard fluoride toothpaste (control group)
Number of subjects: 60
Study: 19468787

Group type: EXPERIMENTAL
Intervention: Pentoxyphylline (800 mg daily) and vitamin E (800 UI daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Historical control group treated with cyclophosphamide for 6 months
Number of subjects: 12
Study: 17315221

Group type: EXPERIMENTAL
Intervention: Burch procedure
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Autologous fascia sling procedure
Number of subjects: 655
Study: 15841813

Group type: EXPERIMENTAL
Intervention: Resting whole salivary secretion rate < or =0.1 mL/min
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Stimulated whole salivary flow rates <0.7 mL/min
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Salivary tests taken on several occasions
Number of subjects: 30
Study: 11045792

Group type: EXPERIMENTAL
Intervention: Tamoxifen and N-[4-hydroxyphenyl] retinamide
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 8956556

Group type: EXPERIMENTAL
Intervention: Non-invasive variceal pressure measurement with the endoscopic gauge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medical treatment of variceal bleeding
Number of subjects: 0
Study: 15374404

Group type: EXPERIMENTAL
Intervention: Mucin-containing artificial saliva
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo liquid
Number of subjects: 85
Study: 2581467

Group type: EXPERIMENTAL
Intervention: Cimetidine 100 mg orally once a day for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30958069

Group type: EXPERIMENTAL
Intervention: 12 µg of formoterol (FOR)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 100 µg of salmeterol (SAL)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 30139419

Group type: EXPERIMENTAL
Intervention: Oral caffeine supplementation (400 mg per dancer, 6.3 mg/kg, range: 4.9 to 8.6 mg/kg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 26747792

Group type: EXPERIMENTAL
Intervention: Aggressive medical management
Number of subjects: 227
Study: 24434055

Group type: EXPERIMENTAL
Intervention: Medical yoga in addition to standard care for 12 weeks
Number of subjects: 6
Study: 22834978

Group type: EXPERIMENTAL
Intervention: Telehealth (TH) and telecare (TC) interventions
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Qualitative semi-structured interviews
Number of subjects: 22
Study: 19056575

Group type: EXPERIMENTAL
Intervention: Iron supplementation (1 mg . kg(‐1) . d(‐1)) from 4 to 9 months
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Iron supplementation (1 mg . kg(‐1) . d(‐1)) from 6 to 9 months
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo only
Number of subjects: 25
Study: 17634458

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol 400 mg subcutaneously at weeks 0, 2, and 4, then every 4 weeks
Number of subjects: 662

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Number of subjects: 662
Study: 15588746

Group type: EXPERIMENTAL
Intervention: Industry-funded studies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-industry-funded studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Industry-funded studies with first authors employed by industry
Number of subjects: 0
Study: 12847475

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg bid)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (250 microg bid)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (5 mg qid)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 10597739

Group type: EXPERIMENTAL
Intervention: Accelerated weekly schedule (AWS) of cisplatin (100 mg/m2 every week for two triplets of three cycles separated by a 5-week interval)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Conventional 3-weekly schedule (CTWS) of cisplatin (100 mg/m2 every 3 weeks for six cycles)
Number of subjects: 101
Study: 8909705

Group type: EXPERIMENTAL
Intervention: SpaceLabs Medical oscillometric blood pressure monitor (neonatal study)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: SpaceLabs Medical oscillometric blood pressure monitor (adult study)
Number of subjects: 127
Study: 1742390

Group type: EXPERIMENTAL
Intervention: Informational newsletter
Number of subjects: 344

Group type: COMPARATOR
Intervention: No informational newsletter
Number of subjects: 344
Study: 6355242

Group type: EXPERIMENTAL
Intervention: Diltiazem 120 mg per day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Diltiazem 240 mg per day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Diltiazem 360 mg per day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High dose diltiazem
Number of subjects: 20
Study: 3919619

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 15
Study: 30151229

Group type: EXPERIMENTAL
Intervention: High-protein diet (+50 g protein per day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal-protein diet
Number of subjects: 14
Study: 26026858

Group type: EXPERIMENTAL
Intervention: Clinician guided feedback
Number of subjects: 22

Group type: COMPARATOR
Intervention: Tibial accelerometry
Number of subjects: 22
Study: 24119101

Group type: EXPERIMENTAL
Intervention: Prostatic urethral lift (PUL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 0
Study: 24331630

Group type: EXPERIMENTAL
Intervention: Enhanced nutritional therapy (n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (n = 25)
Number of subjects: 50
Study: 19350378

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention (MLH-I)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Awaiting psychosocial intervention (MLH-W)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (mothers without HIV)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Composite biomarker index (CBI)
Number of subjects: 150
Study: 18768040

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (group A)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (group P)
Number of subjects: 26
Study: 16896724

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 19‐norandrostenedione
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 14557756

Group type: EXPERIMENTAL
Intervention: FTY720 (0.125, 0.25, 0.5, 1.0, 2.5, or 5.0 mg/day)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: FTY720
Number of subjects: 76
Study: 10979067

Group type: EXPERIMENTAL
Intervention: No cleansing, urinate into a clean container (n = 77)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Midstream urine sample with perineal cleansing (n = 84)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Midstream urine sample with perineal cleansing and vaginal tampon (n = 81)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Combined cleansing, midstream groups
Number of subjects: 242
Study: 8774628

Group type: EXPERIMENTAL
Intervention: Antioxidant regimen (vitamins E, C and N‐acetylcysteine)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Antioxidant regimen (vitamins E, C and N‐acetylcysteine) in chemotherapy group
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo in chemotherapy group
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Antioxidant regimen (vitamins E, C and N‐acetylcysteine) in radiotherapy group
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo in radiotherapy group
Number of subjects: 25
Study: 1377359

Group type: EXPERIMENTAL
Intervention: Moricizine
Number of subjects: 1325

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1325
Study: 31168845

Group type: EXPERIMENTAL
Intervention: Curcuminoids plus piperine (500 mg curcuminoids and 5 mg piperine daily)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 29521740

Group type: EXPERIMENTAL
Intervention: Antiviral therapy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no antiviral therapy)
Number of subjects: 200
Study: 26842679

Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 2827

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2827
Study: 24519908

Group type: EXPERIMENTAL
Intervention: Early physical activity (PA) measured by implanted devices, averaged over the earliest 30-day study period.
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: Early physical activity (PA) measured by implanted devices.
Number of subjects: 781
Study: 22564713

Group type: EXPERIMENTAL
Intervention: LTC (lonafarnib + carboplatin + paclitaxel)
Number of subjects: 105

Group type: COMPARATOR
Intervention: TC (carboplatin + paclitaxel)
Number of subjects: 105
Study: 19851772

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 0
Study: 17914203

Group type: EXPERIMENTAL
Intervention: Capsular tension ring (CTR) implantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (without CTR)
Number of subjects: 0
Study: 15685236

Group type: EXPERIMENTAL
Intervention: Intensive followup
Number of subjects: 6
Study: 12134226

Group type: EXPERIMENTAL
Intervention: anti‐HCV regimen (interferon‐alpha2a and ribavirin)
Number of subjects: 36
Study: 9708400

Group type: EXPERIMENTAL
Intervention: Nelfinavir (NFV)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Saquinavir (SQV)
Number of subjects: 29
Study: 7893033

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (70%)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (no nitrous oxide)
Number of subjects: 38
Study: 2527729

Group type: EXPERIMENTAL
Intervention: Seven low-dose oral contraceptive preparations (monophasic and triphasic levonorgestrel, monophasic and biphasic desogestrel, monophasic norethisterone, monophasic cyproterone acetate, triphasic gestodene)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Seven low-dose oral contraceptive preparations
Number of subjects: 55
Study: 326635

Group type: EXPERIMENTAL
Intervention: Antibiotics effective against obligate anaerobes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31587982

Group type: EXPERIMENTAL
Intervention: Intravenous Dexamethasone (DEX) 0.15 mg/kg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 100
Study: 31036337

Group type: EXPERIMENTAL
Intervention: Combination treatment consisting of a slow infusion of 20 mg/kg ferric carboxymaltose, 40,000 U subcutaneous erythropoietin alpha, 1 mg subcutaneous vitamin B12, and 5 mg oral folic acid.
Number of subjects: 1006

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1006
Study: 28719430

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hscTnT) assay
Number of subjects: 605

Group type: COMPARATOR
Intervention: Contemporary cardiac troponin I (cTnI) assay
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hscTnT) elevation
Number of subjects: 605
Study: 27068432

Group type: EXPERIMENTAL
Intervention: Rutgeerts score (RS) assessment by endoscopists
Number of subjects: 39

Group type: COMPARATOR
Intervention: Therapeutic initiation based on RS ≥ i2
Number of subjects: 39

Group type: COMPARATOR
Intervention: Therapeutic initiation based on RS > i2
Number of subjects: 39
Study: 25172229

Group type: EXPERIMENTAL
Intervention: Topical petrolatum gel
Number of subjects: 50

Group type: COMPARATOR
Intervention: Topical silver sulfadiazine with gauze dressings
Number of subjects: 50
Study: 21455591

Group type: EXPERIMENTAL
Intervention: Circumferential abdominoplasty
Number of subjects: 40

Group type: COMPARATOR
Intervention: Augmentation mammoplasty with mastopexy
Number of subjects: 40
Study: 19128802

Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg oid) for 6 months
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Trandolapril (4 mg oid) for 6 months
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of verapamil and trandolapril for additional 6 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (Trandolapril)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (Verapamil)
Number of subjects: 20
Study: 17337881

Group type: EXPERIMENTAL
Intervention: Automatic Positive Airway Pressure (APAP)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Manual Continuous Positive Airway Pressure (CPAP)
Number of subjects: 21
Study: 15564360

Group type: EXPERIMENTAL
Intervention: Total sleep deprivation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Undisturbed night sleep
Number of subjects: 20
Study: 11167209

Group type: EXPERIMENTAL
Intervention: 80 mg of elemental iron a day for the first two months after childbirth
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 80 mg of elemental iron + 0.35 mg of folic acid a day for the first two months after childbirth
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 90